BIOLASE, INC【BIOLQ】

時価総額

$36.6

PER

歯科用レーザー機器の有力企業。ウォーターレーザーシステムと消耗品、教育アカデミー、臨床試用プログラムを展開。2023年1月の公募で約990万ドルと、2024年2月の公募で約700万ドル調達。米国中心に国際展開、ドイツ2011年、インド2012年に直接販売、2023年海外比率31%。

株価業績

サマリーテーブルに戻る

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Net loss	-	-	-	-	-	-	-	-22	-18	-17	-16	-29	-21
Depreciation	1	1	1	1	1	1	1	1	1	0	0	0	3
Provision for bad debts	-	0	0	1	0	-0	0	0	2	1	-0	0	1
Inventory Excess And Obsolescence	-	-	-	-	-	-	-	-	-	-	-	-	1
Inventory Write-down	-	0	1	1	1	0	1	0	0	-1	-0	1	-
Amortization of debt issuance costs	0	0	0	0	-	-	-	0	0	0	0	1	0
Patent litigation mark-to-market	-	-	-	-	-	-	-	-	-	-	0	-	-
Change in fair value of warrants	-	-	-	-	-	-	-	-	-	-6	-	-	-0
Issuance Of Restricted Shares	-	-	-	-	-	-	-	-	-	-	0	0	-
Issuance costs for warrants	-	-	-	-	-	-	-	-	-	2	-	-	0
Stock-based compensation	2	2	2	1	-	3	2	3	3	3	2	2	1
Gain on debt forgiveness	-0	-	-	-	-	-	-	-	-	-	3	-	-
Gain on disposal of fixed assets	-	-	-	-	-	-	-	-	-	-	-	-	0
Accounts receivable	6	3	-0	-1	0	1	0	1	-1	-4	1	2	-0
Inventory	5	0	1	2	1	2	-0	0	-1	1	1	6	-1
Prepaid expenses and other current assets	1	-0	-0	0	0	-0	0	0	-0	-1	-0	1	-2
Accounts payable and accrued liabilities	4	-0	-1	0	-1	3	-5	2	-3	-2	2	4	-2
Deferred revenue	-	-	-	-	-	-	-	-0	0	-0	0	-0	0
Net cash and cash equivalents used in operating activities	-13	-2	-9	-	-	-	-	-14	-13	-13	-17	-27	-14
Purchases of property, plant, and equipment	0	1	1	0	2	1	1	1	0	0	1	4	1
Proceeds from Sale of Property, Plant, and Equipment	-	-	-	-	0	-	-	0	-	-	-	-	0
Net cash and cash equivalents used in investing activities	-0	-1	-1	-	-	-	-	-1	-0	-0	-1	-4	-1
Gross proceeds	17	-	5	51	-	10	-	-	9	-	-	6	10
Proceeds from the sale of Convertible Preferred Stock, net of fees	-	-	-	-	-	-	-	-	-	-	-	-	5
Proceeds From Sale Of Common Stock Warrants	-	-	-	-	-	-	-	-	-	-	-	-	2
Principal payment on loan	-	-	-	-	-	-	-	-	-	-	-	1	0
Payments of equity offering costs	-	-	-	-	-	-	-	0	-	1	1	-	-
Payments of debt issuance costs	-	0	0	0	-	-	-	1	0	0	0	-	-
Proceeds from Warrant Exercises	0	0	-	-	-	-	-	-	-	0	17	0	0
Procees from the exercise of preferred share warrants	-	-	-	-	-	-	-	-	-	-	-	-	1
Proceeds from exercise of stock options	-	-	-	-	-	-	-	0	0	-	0	-	-
Net cash and cash equivalents provided by financing activities	15	2	9	-	-	-	-	11	11	24	30	5	17
Effect of exchange rate changes	-	-	-	-	-	-	-	-	-	-	-	-0	0
Increase (decrease) in cash and cash equivalents	-	-	-	-	-	-	-	-4	-2	12	12	-26	2
Cash paid for interest	-	-	-	-	-	-	-	0	2	2	2	2	2
Cash received for interest	-	-	-	-	-	-	-	-	-	0	0	0	0
Income Taxes Paid, Net	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash paid for operating leases	-	-	-	-	-	-	-	-	-	-	0	0	0
Non-cash settlement of liability	-	-	-	-	-	-	-	-	-	-	1	-	-
Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation	-	-	-	-	-	-	-	-	-	-	0	1	0
Dividends, Preferred Stock, Stock	-	-	-	-	-	-	-	-	-	17	1	0	-
Forgiveness of debt	-	-	-	-	-	-	-	-	-	0	-	-	-
Receivable From WarrantsExercised And Included In Prepaid And Other Current Assets	-	-	-	-	-	-	-	-	-	-	-1	-	-
Non-cash property, plant and equipment additions acquired under inventory	-	-	-	-	-	-	-	-	-	-	-	-	3
Common stock issued upon exercise of preferred stock	-	-	-	-	-	-	-	-	-	-	-	-	22
Debt Conversion, Converted Instrument, Amount	-	-	-	-	-	-	-	1	0	0	-	-	-